• Update on de-intensification strategies - C. Simon (Switzerland)
• HPV-positive oropharyngeal cancers: immunological control and impact of immunotherapy - M.J.P. Welters (Netherlands)
• Clinical and molecular factors modulating response and prognosis of HPV-positive cancers - J.P. Klussmann (Germany)
• Improving efficacy of immunotherapy with combinations in HPV-positive cancers - E. Massarelli (USA)

• Etiologic role in global perspective - L. Alemany (Spain)
• Should there be screening for HPV-driven oropharyngeal cancer? - A. Kreimer (USA)
• Biomarkers of choice: oral HPV. Understanding the strength and limitations - A. D’Souza (USA)
• HPV serology and screening for oropharyngeal cancers - K. Anderson (USA) & T. Waterboer (Germany)

• Oral HPV vs. serology - A. D’Souza (USA)
• Implications of high-risk biomarker seropositivity: Bridging lessons from CIN to OPC - H. Robbins (France)
• What to do with high risk biomarker positive? Lessons from unknown primary & prophylactic mucosectomy - D. Eisele (USA)
• Current Screening Trial Designs - A. Day (USA)

• Plasma Circulating Tumor HPV DNA for Early Detection of Cancer Recurrence in HPVassociated Oropharyngeal Cancer - B. Chera (USA)
• HPV antibodies and risk of recurrence - K. Lang Kuhs (USA)
• Oral HPV - E. Rettig (USA)
• What would you do if identified high-risk individual in terms of diagnostics? - C. Fakhry (USA)

• Single cell sequencing analysis of HPV positive OPSCC - S. Puram (USA)
• HPV ctDNA quantification and characterization - S. Bratman (Canada)
• Molecular characteristics by smoking - J. Zevallos (USA)
• A sensitive and specific marker for HPV+ oropharyngeal cancer that occurs up to 20 years before disease onset - P. Brennan (France)

Recurrent Respiratory Papilloma (RRP) is a benign disease affecting the larynx of children and adults caused by infection with low-risk HPV 6 or 11. The need for recurrent surgery and its devastating effects on voice and breathing make treating this disease a great challenge. This session highlights collaborative research efforts that attempt to overcome the challenges of treating a rare and orphan disease. Multi-institutional efforts are ongoing in the natural history of disease, genetics, immunology, and novel therapeutics in the search for effective therapies.

• RRP in the wild: tracking treatment and natural history - M. Amin (USA)
• Clinical consensus building for the use of systemic Avastin in RRP - P. Mudd (USA)
• Coordination of patient advocacy groups for the monitoring of systemic Avastin - S. Best (USA)
• RNA sequencing for target genetic markers in pediatric RRP - A. de Alarcon (USA) & C. Allen (USA)